Research hero image

Research

ESMO 2022: Surprise and dismay over poor post-surgery immunotherapy results thumbnail image

ESMO 2022: Surprise and dismay over poor post-surgery immunotherapy results

Research
By D’Ann George, PhD, Medical Writer https://www.kidneycancer.org/explore-your-treatment-options/ Three separate phase III clinical trials showed that people with kidney cancer who had undergone nephrectomy (kidney removal) but whose cancer had not yet metastasized, or spread, did not benefit from adjuvant immunotherapy.  The trials were testing the theory that adjuvant immunotherapy, which is given after surgery to prevent cancer from returning, might…
Read More
ESMO 2022: First triplet study in kidney cancer shows promising results thumbnail image

ESMO 2022: First triplet study in kidney cancer shows promising results

Research
By D’Ann George, PhD, Medical Writer https://www.youtube.com/watch?v=dUJDnoEfb0A Dr. Toni Choueiri discusses the COSMIC-313 trial. At the recent European Society of Medical Oncology congress in Paris, oncologists eagerly awaited results from the ground-breaking phase III COSMIC-313 trial for two reasons:  it tested the effectiveness of a three-drug combination - cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) - for the first…
Read More
1 … 8 9 10 11 12 … 17